Albany, New York, June 16, 2017 : “T Cell Specific Surface Glycoprotein CD28” (TP44 or CD28) – CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Systemic Lupus Erythematosus, Acute Renal Failure (ARF) (Acute Kidney Injury), Arthritis, B-Cell Chronic Lymphocytic Leukemia, Gastrointestinal Radiation Toxicity, Hypersensitivity, Kidney Transplant Rejection, Multiple Sclerosis, Pancreatitis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Sicca Syndrome (Sjogren), Skin And Soft Tissue Infections, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes) and Uveitis.

Request For Free Sample @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157702

The latest report T Cell Specific Surface Glycoprotein CD28 – Pipeline Review, H1 2017, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
– The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
– The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Browse Full Report With TOC @ http://www.marketresearchhub.com/report/t-cell-specific-surface-glycoprotein-cd28-tp44-or-cd28-pipeline-review-h1-2017-report.html

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) – Overview
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) – Companies Involved in Therapeutics Development
Atox Bio Ltd
Bristol-Myers Squibb Company
Five Prime Therapeutics Inc
OSE Immunotherapeutics
TheraMAB LLC
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) – Drug Profiles
ALPN-101 – Drug Profile
Product Description

Continue…..

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1157702

 

About Market Research Hub:            

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,

Albany, NY 12207,

United States

Toll Free: 866-997-4948 (US-Canada)

Tel: +1-518-621-2074

Email: [email protected]

Website: http://www.marketresearchhub.com/

Read More Related News: https://www.industrynewsanalysis.com/

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Copyright © 2017 PressReleasePost.com

Log in with your credentials

or    

Forgot your details?

Create Account

%d bloggers like this:
Join Our Newsletter
Signup today for free & be the first to get notified on exciting updates!
Your Information will never be shared with any third party.